Purpose: The purpose of this study was to assess the prognostic impact of androgen receptor (AR) expression in patients with triple-negative breast cancer (TNBC).
Methods/patients: 101 patients treated for primary TNBC without distant metastasis from 1999 to 2015 were identified from breast surgery database. Kaplan-Meier and Cox regression models evaluated disease-free survival (DFS) and overall survival (OS).
Results: AR expression was positive (IHC>1%) in 40% of patients. OS at 36 and 60 months was 86% and 80% in AR-negative patients, and 100% and 96% in AR-positive patients (log rank test 0.036). DFS at 36 and 60 months was 78% and 68% in AR-negative and 92% and 89% in AR-positive (log rank test 0.075).
Conclusions: Patients without AR expression have a significant correlation with poor outcome.